http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2424644-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_187c6fe40c5ba795643e0120c378f974 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2ee6603905effc235e36caa42583512 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 |
| filingDate | 2005-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_245314e27694aa59c6b91b535b8302c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3787fcb99461e52da4df4917d3085731 |
| publicationDate | 2013-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2424644-T3 |
| titleOfInvention | Compounds, formulations and methods to treat or prevent inflammatory skin disorders |
| abstract | A composition comprising: at least one between an α2 adrenergic receptor agonist and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; for use in the treatment or prevention of an inflammatory skin disorder and the symptoms associated therewith, in which said composition is to be administered topically to the skin of a patient in need of said treatment or prevention, in which at least one of an α2 adrenergic receptor agonist and one of its pharmaceutically acceptable salts is selected from the group consisting of brimonidine and oxymetazoline, and wherein said inflammatory skin disorder is selected from the group consisting of dermatitis, including contact dermatitis, Atopic dermatitis, seborrheic dermatitis, numular dermatitis, generalized exfoliative dermatitis, porestasis dermatitis, chronic simple lichen, disorders of the hair follicles and sebaceous glands, including acne, rhinophyma, perioral dermatitis and pseudo-folliculitis of the beard and inflammatory reactions, including drug rashes , erythema multiforme, erythema nodosum and granuloma an ular |
| priorityDate | 2004-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 232.